OrsoBio is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for severe metabolic disorders such as diabetes, severe dyslipidemia, and lipodystrophies. The company's mission is to restore energy homeostasis in patients by targeting pathways crucial for maintaining energy balance. OrsoBio focuses on addressing the underlying causes of these disorders, aiming to revolutionize treatment options and improve patient outcomes.
OrsoBio has made significant strides in its field, including presenting phase and preclinical data at major scientific conferences like the American Diabetes Association’s Scientific Sessions and the American Heart Association’s Scientific Sessions. The company secured $60 million in Series A financing to advance its metabolic portfolio, highlighting strong investor confidence in its potential. These achievements underscore OrsoBio's impact on the biopharmaceutical landscape and its commitment to advancing treatments for metabolic disorders.
